ÂÜÀòÂÒÂ×

Stephen P. Hale is a seasoned leader in the biopharmaceutical industry, currently serving as Founder and CEO of DG Medicines since July 2021, while also contributing to Stablix, Inc. and Totus Medicines as a Scientific Advisory Board member. With extensive experience as an independent consultant in biotech, pharma, and venture capital since 2017, Stephen has successfully led research and development efforts in various roles, including Senior Vice President at Dewpoint Therapeutics, where significant collaborations with Bayer and Merck were established. Stephen’s notable track record includes senior leadership positions at Ensemble Therapeutics, Praecis, and Phylos, holding pivotal responsibilities in drug discovery and development initiatives that garnered substantial funding and advanced multiple therapeutic programs. Stephen's academic credentials include a Ph.D. in Biochemistry/Enzymology from the University of Maryland and a postdoctoral fellowship at the Massachusetts Institute of Technology.